论文期刊

Therapeutic Drug Monitoring and Safety of Voriconazole Therapy in Patients with




作者: Taotao Wang, Yalin Dong*
发表/完成日期: 2018-04-04
期刊名称: International Journal of Infectious Diseases
期卷:
相关文章:
论文简介
The purpose of this study was to investigate the pharmacokinetic profile and safety of voriconazole treatment in patients with Child-Pugh class B and C cirrhosis. Liver cirrhosis patients who had received the recommended voriconazole maintenance dose (group A) or halved maintenance dose (group B), orally or intravenously, were included. Voriconazolerelated adverse events (AEs) were defined according to the Common Terminology Criteria for Adverse Events. A total of 110 trough plasma concentrations of voriconazole (C-min) were measured in 78 patients. There was a significant difference in voriconazole C-min between group A and group B (C-min, 6.95 +/- 3.42 mg/l vs. 4.02 +/- 2.00 mg/l; p < 0.001). No significant difference in voriconazole C-min between Child-Pugh class B and C cirrhosis patients was observed in either of the two groups. The international normalized ratio and co-medication with a CYP2C19 inhibitor had a significant effect on voriconazole C-min in group B. The incidence of AEs in group A was 26.5% and in group B was 15.9%, and 87.5% of AEs developed within 7 days after starting voriconazole treatment. These results suggest that the recommended dose and halved maintenance dose may be inappropriate in patients with Child-Pugh class B and C cirrhosis due to the high C-min, and that voriconazole C-min should be monitored earlier to avoid AEs.
版权所有:西安交通大学 站点设计:网络信息中心 陕ICP备05001571号 IPhone版本下载 IPhone版本下载    Android版本下载 Android版本下载
欢迎您访问我们的网站,您是第 位访客
推荐分辨率1024*768以上 推荐浏览器IE7 Fifefox 以上